title: Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.
authors.affiliation: University of Brasilia, Brasilia, Brazil.
authors.forename: Ana C V
authors.initials: AC
authors.lastname: Oliveira
authors.forename: Licia M H
authors.initials: LM
authors.lastname: Mota
authors.forename: Leopoldo L
authors.initials: LL
authors.lastname: Santos-Neto
authors.forename: Marisol
authors.initials: M
authors.lastname: Simões
authors.forename: Olindo A
authors.initials: OA
authors.lastname: Martins-Filho
authors.forename: Pedro L
authors.initials: PL
authors.lastname: Tauil
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D001938:Brazil / Q000453:epidemiology; D002648:Child; D000075202:Contraindications; D005260:Female; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects / Q000276:immunology; D007117:Immunization, Secondary / Q000009:adverse effects; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000069285:Infliximab; D007555:Isoxazoles / Q000494:pharmacology / Q000627:therapeutic use; D000077339:Leflunomide; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D008875:Middle Aged; D012189:Retrospective Studies; D012216:Rheumatic Diseases / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D000069283:Rituximab; D012595:Scleroderma, Systemic / Q000188:drug therapy / Q000276:immunology; D015004:Yellow Fever / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D022341:Yellow Fever Vaccine / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D022341:Yellow Fever Vaccine; D000069283:Rituximab; D000069285:Infliximab; D000077339:Leflunomide